Maob Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Monoamine Oxidase B (MAOB) protein is a mitochondrial flavin adenine dinucleotide (FAD)-dependent enzyme that plays a critical role in dopamine catabolism, trace amine metabolism, and xenobiotic detoxification. It is primarily expressed in the brain (substantia nigra, striatum, hippocampus) and peripheral tissues including platelets, liver, and intestines. MAOB is a key therapeutic target for Parkinson's disease (PD) and has been implicated in Alzheimer's disease (AD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS).
| Monoamine Oxidase B (MAOB) |
|---|
| Protein Name | Monoamine Oxidase B |
| Gene | MAOB |
| UniProt ID | P50395 |
| PDB ID(s) | 1S2E, 1S3B, 2V7Z, 6BW2 |
| Molecular Weight | 58.7 kDa |
| Subcellular Localization | Mitochondrial outer membrane |
| Protein Family | Monoamine oxidase family |
| Cofactor | FAD (covalently bound) |
| Expression | Brain, platelets, liver, intestines |
The MAOB protein consists of two main domains:
- FAD-binding domain (residues 1-206): Contains the catalytic core with covalently bound FAD cofactor at position 397
- Substrate-binding domain (residues 207-527): Forms the active site pocket that determines substrate specificity
- C-terminal transmembrane helix: Anchors the enzyme to the mitochondrial outer membrane
The substrate-binding pocket exhibits distinct specificity compared to MAOA:
- Phenylethylamine-binding site: High affinity for phenylethylamine (Km ~ 20 µM)
- Ile199 residue: Key determinant of B-selective inhibitors
- Gln206 and Met445: Important for substrate positioning
| Feature |
MAOB |
MAOA |
| Substrate preference |
Phenylethylamine |
Serotonin |
| Inhibitor sensitivity |
Selegiline, rasagiline |
Clorgyline |
| Brain expression |
Higher in substantia nigra |
Higher in cortex |
| Km for dopamine |
~100 µM |
~50 µM |
MAOB catalyzes the oxidative deamination of amines with the following reactions:
-
Primary substrates:
- Phenethylamine (Km ~ 20 µM, highest affinity)
- Benzylamine (Km ~ 200 µM)
- Dopamine (Km ~ 100 µM in human brain)
-
Reaction chemistry:
- R-CH₂-NH₂ + O₂ + H₂O → R-CHO + NH₃ + H₂O₂
- Produces hydrogen peroxide as a byproduct
- Neurotransmitter catabolism: Primary pathway for dopamine breakdown in the substantia nigra
- Trace amine metabolism: Catalyzes phenylethylamine and other trace amines
- Xenobiotic metabolism: Metabolizes exogenous amines including MPTP
- Reactive oxygen species generation: Produces H₂O₂, contributing to oxidative stress when overactive
- Brain: Highest expression in substantia nigra pars compacta, striatum, and hippocampus
- Peripheral: Platelets, liver, intestines, lungs
- Cellular: Primarily mitochondrial outer membrane of neurons and astrocytes
MAOB is a primary therapeutic target in PD:
- Dopamine catabolism: MAOB degrades dopamine in the striatum, reducing available neurotransmitter
- Oxidative stress: H₂O₂ production contributes to dopaminergic neuron vulnerability
- MPTP bioactivation: MAOB converts MPTP to the toxic MPP+ metabolite
- Selective vulnerability: Substantia nigra dopaminergic neurons have high MAOB expression
MAOB inhibitors (selegiline, rasagiline, safinamide) provide:
- Symptomatic relief by prolonging dopamine action
- Potential neuroprotective effects through reduced oxidative stress
- Disease-modifying potential in early PD
MAOB involvement in AD includes:
- Elevated activity: MAOB activity increased in AD brain (40-70%)
- Hydrogen peroxide production: Contributes to Aβ-induced oxidative stress
- NFT association: Colocalizes with neurofibrillary tangles
- Cognitive decline: Higher MAOB activity correlates with faster progression
- Increased activity: MAOB elevated in HD caudate nucleus and cortex
- GABA reduction: May contribute to GABAergic neuron dysfunction
- Energy metabolism: Affects mitochondrial function in striatal neurons
- Motor neuron vulnerability: MAOB expression in spinal cord motor neurons
- Oxidative stress: Contributes to ROS in ALS pathogenesis
- Glutamate excitotoxicity: May interact with glutamatergic systems
| Drug |
Approval |
Indication |
Daily Dose |
| Selegiline |
1989 |
Early PD |
5-10 mg |
| Rasagiline |
2006 |
Early/mid PD |
1 mg |
| Safinamide |
2015 |
Mid/late PD |
50-100 mg |
- Irreversible inhibition: Selegiline and rasagiline form covalent bonds with FAD
- Reversible inhibition: Safinamide binds reversibly
- Dopamine enhancement: Prevents dopamine breakdown, extending its half-life
- Neuroprotection: Reduces oxidative stress and excitotoxicity
- Common: Nausea, orthostatic hypotension, insomnia
- Off-target: Tyramine interaction (cheese effect) - minimal with selective MAOB inhibitors
- Severe: Rare reports of hepatotoxicity
- Multi-target inhibitors: MAOB + COMT inhibitors for enhanced dopamine elevation
- Neuroprotective derivatives: Fendrixiline, mofegiline
- Gene therapy: AAV-MAOB shRNA for long-term reduction
- Blood-brain barrier penetration: Novel lipophilic analogs
- Platelet MAOB activity: Proposed biomarker for PD progression
- CSF MAOB: Investigated as diagnostic marker
- PET ligands: [^11C]L-deprenyl for MAOB imaging
- MAOB polymorphisms: Associated with PD risk and age of onset
- Gene-environment interactions: MAOB × pesticide exposure in PD
The study of Maob Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.